RxDoctor Payments Data

Robert Bae, MD

Urology · Newport Beach, CANPI 1467433326

Payments from drug & device makers

$1,744in general payments, 2019–2025

Across 72 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Boston Scientific$201
  • 180 Medical, Inc.$164
  • Astellas Pharma US Inc$149
  • Urogen Pharma, Inc.$81
  • Sumitomo Pharma America, Inc.$48
  • plus $50 from 2 others

What the payments were for

  • Food & beverage$1,744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,744 in reported general payments places this provider in the 40th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$355,702
Medicare patients
654
Services billed
3,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron63$73,373
MyrbetriqMirabegron66$56,799
Tamsulosin Hcl621$10,785
Alfuzosin Hcl ErAlfuzosin Hcl434$10,083
Finasteride555$7,521
Testosterone35$4,139
Silodosin31$3,332
Dutasteride57$1,852
Cefpodoxime Proxetil31$1,774
Potassium Citrate ErPotassium Citrate11$1,455
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$1,299
Oxybutynin Chloride ErOxybutynin Chloride28$1,003
Cefdinir54$908
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav60$518
Tadalafil18$397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$48$73,37363 claims
Astellas Pharma US IncMyrbetriq$149$56,79966 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,324 urology providers in California.

Other urology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →